2 unknown, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 2 | Unknown 2 |
Follow Sara V. Latorre: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy ARI-0001 cells - Acute Lymphoid Leukemia | Phase 2 | Unknown | Sara V. Latorre | 50 | 2021-05-11 | 2024-06-26 |
| Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. Adult differentiated autologous T-cells with anti-BCMA specificity - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Sara V. Latorre | 73 | 2020-05-27 | 2023-08-28 |
| Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy Adult differentiated autologous T-cells - Leukemia, Lymphoma | Phase 1 | Completed | Sara V. Latorre | 50 | 2017-06-15 | 2023-08-28 |
Leukemia (1) · Lymphoma (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
CTL019 chimeric antigen receptor (1)
Spain (3)
Carlos Fernandez de Larrea, MD,PhD (1)
PMID 32528460, PMID 33010231, PMID 34876408, PMID 37414060, PMID 37905734, PMID 39602341, PMID 40951523, PMID 40987492, PMID 41429239, PMID 41651004
2019 (1)